[go: up one dir, main page]

US20070015781A1 - Certain substituted spirocyclic lactams and use thereof as pharmaceuticals - Google Patents

Certain substituted spirocyclic lactams and use thereof as pharmaceuticals Download PDF

Info

Publication number
US20070015781A1
US20070015781A1 US10/574,536 US57453606A US2007015781A1 US 20070015781 A1 US20070015781 A1 US 20070015781A1 US 57453606 A US57453606 A US 57453606A US 2007015781 A1 US2007015781 A1 US 2007015781A1
Authority
US
United States
Prior art keywords
alkyl
compound
free base
addition salt
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/574,536
Inventor
Yves Auberson
Ralf Glatthar
Rhys Salter
Oliver Simic
Marina Tintelnot-Blomley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20070015781A1 publication Critical patent/US20070015781A1/en
Priority to US11/823,311 priority Critical patent/US7655686B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to novel 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions containing them.
  • the compounds may exist in optically active form or in the form of mixtures of optical isomers, e.g. in the form of racemic mixtures. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention.
  • the compounds of the formula I and their salts may contain a radioisotope, such as tritium, 14 C, 11 C or 18 F. All radiolabeled compounds and their use as biomarkers, in vitro or in vivo imaging agents, or in biochemical assays, e.g. binding assays, are part of the present invention.
  • Substituents on the above defined non-aromatic groups are selected from hydroxy, halogen, carbamoyl, carboxy, hydroxy(C 1-4 )alkyl, (C 1-4 )alkoxy, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkoxy, (C 1-4 )alkylsulfanyl, (C 1-4 )alkoxycarbonyl, (C 1-4 )alkylcarbonyloxy, (C 1-4 )alkylcarbonyl, (C 1-4 )alkylsulfonyl, cyano, oxo, (C 3-7 )cycloalkyl, hetero(C 3-7 )cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl.
  • (C 3-7 )cycloalkyl or hetero-(C 3-7 )cycloalkyl groups can also be fused with an additional (C 3-7 )cycloalkyl, hetero(C 3-7 )cycloalkyl, or an aromatic or heteroaromatic ring.
  • Substituents on above defined aromatic or heteroaromatic groups are selected from halogen, hydroxy, cyano, nitro, trifluoromethyl, benzyloxy, phenoxy, SO 2 NH 2 , NHSO 2 (C 1-3 ) alkyl, carboxy, (C 1-4 )alkyloxycarbonyl, carbamoyl, (C 1-4 )alkylcarbamoyl, (C 1-4 )alkylsulfonyl, (C 1-4 )alkylcarbonyloxy, (C 1-4 )alkylcarbonyl, (C 1-6 )alkyl, (C 1-4 )alkoxy, hydroxy(C 1-4 )alkyl, aryl, heteroaryl or an optionally substituted amino group.
  • Substitutents on amino or carbamoyl groups can be one or two groups selected from (C 1-4 )alkyl, (C 1-4 )alkoxy(C 1-4 )alkyl, (C 1-4 )alkoxycarbonyl, aryl(C 1-4 )alkyloxycarbonyl or heteroaryl(C 1-4 )alkyloxycarbonyl.
  • Aryl is an aromatic 6-membered ring optionally mono-, di- or tri-substituted by, independently, hydroxy, cyano, trifluoromethyl, halogen, carboxy, (C 1-4 )alkyloxycarbonyl, (C 1-4 )alkylcarbamoyl, (C 1-4 )alkylsulfonyl, (C 1-4 ) alkylcarbonyloxy, (C 1-4 )alkylcarbonylamino, (C 1-4 )alkylcarbonyl, (C 1-6 )alkyl, (C 1-4 )alkoxy or hydroxy(C 1-4 )alkyl.
  • Aryl groups can also be fused with a (C 3-7 )cycloalkyl, hetero(C 3-7 )cycloalkyl or additional aromatic or heteroaromatic ring (e.g. to form a naphthyl, quinolinyl or indolyl group).
  • Heteroaryl is an aromatic 5- or 6-membered ring, in which 1, 2 or 3 atoms are heteroatoms independently selected from O, N and S. Heteroaryl is, for example, 1-methyl-1H-pyrrol-2-yl or 1H-imidazol-2-yl. It can also be fused with a cycloalkyl or additional aromatic or heteroaromatic ring (e.g. to form a quinolinyl or indolyl group).
  • Halogen denotes fluorine, bromine, chlorine or iodine.
  • Any alkyl, alkenyl, alkynyl or alkoxy group is straight or branched.
  • carbon containing groups and molecules contain 1 to 8, preferably 1 to 6, more preferably 1 to 4, carbon atoms.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 1 is hydrogen.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 2 is aryl, preferably phenyl, more preferably unsubstituted phenyl.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 3 is —CH(R e )C( ⁇ O)N(R a )R b or —(CH 2 ) k N(R c )R d , wherein k is 0;
  • R a is hydrogen;
  • R b is (C 1-8 )alkyl or (C 5-9 )bicycloalkyl such as bicycloheptyl;
  • R c is hydrogen;
  • R d is optionally substituted aryl(C 1-4 )alkyl, preferably benzyl substituted in the phenyl ring by (C 1-4 )alkyl, or is optionally substituted (C 3-7 )cycloalkyl, preferably cyclopropyl substituted by phenyl optionally substituted by halogen, such as bromine, or is 4-chromanyl optionally substituted, preferably by halogen and/
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 4 is (C 1-8 )alkyl, or is (C 1-8 )alkyl substituted, preferably mono-substituted, by (C 3-7 )cycloalkyl, preferably cyclopropyl, by halogen, such as fluorine, by (C 1-4 )alkoxy, or by hydroxy, or is (C 2-6 )alkenyl optionally substituted, preferably mono-substituted, by hydroxy, or is (C 2-6 )alkynyl, or is aryl, preferably phenyl, preferably unsubstituted phenyl.
  • R 4 is (C 1-8 )alkyl, or is (C 1-8 )alkyl substituted, preferably mono-substituted, by (C 3-7 )cycloalkyl, preferably cyclopropyl, by halogen, such as fluorine
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 4 is 2,2,3,3-tetratritiopropyl.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 5 is (C 1-8 )alkyl, preferably (C 1-4 )alkyl.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R 6 is hydrogen or halogen, preferably hydrogen or fluorine.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which m is 1.
  • the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which p is 1.
  • the invention relates to a process for the preparation of the compounds of the formula I and their salts, comprising the steps of acylating a compound of the formula wherein R 1 , R 2 and R 3 are as defined above for the formula I, with an acid of the formula wherein R 4 , R 5 , R 6 , m and p are as defined above for the formula I, or an activated form, such as an ester or an acid halogenide, thereof and recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.
  • reaction can be effected according to conventional methods, for example as described in the examples.
  • the compounds of the formula I can also be produced by further conventional processes, e.g. as described in the examples.
  • the starting materials of the formulae II and III are known or may be prepared according to conventional procedures starting from known compounds, for example as described in the examples.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • agents of the invention exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.
  • the agents of the invention are inhibitors of aspartic proteases and can be used for the treatment of disorders involving processing by such enzymes. Particularly they inhibit beta-secretase and as such inhibit the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils.
  • agents of the invention exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter “markers”, for the selective labeling of BACE (beta-secretase cleaving enzyme).
  • agents of the invention are useful as markers for labeling BACE in vitro or in vivo (see Examples 9 and 10).
  • the agents of the invention are therefore useful, for instance, for determining the levels of active site occupancy of a drug acting at BACE, or for diagnostic purposes for diseases resulting from a dysfunction of BACE-related processes, and for monitoring the effectiveness of pharmacotherapies of such diseases.
  • the present invention also provides an agent of the invention for use as a marker for neuroimaging.
  • the present invention provides a composition for labeling brain and peripheral structures involving BACE in vivo and in vitro comprising an agent of the invention.
  • the present invention provides a method for labeling brain and peripheral structures involving BACE in vitro or in vivo, which comprises contacting brain or peripheral tissue with an agent of the invention.
  • the method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure.
  • Said further step may be effected by observing the target structure using autoradiography, positron emission tomography (PET), or any device allowing detection of radioactive radiations.
  • PET positron emission tomography
  • Recombinant BACE (extracellular domain, expressed in baculovirus and purified using standard methods) at 6 nM concentration is incubated with the test compound at various concentrations for 1 hour at room temperature in 100 mM acetate buffer, pH 4.5, containing 0.1% CHAPS.
  • Synthetic peptide substrate Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(DNP) is added to a final concentration of 3 ⁇ M and the increase in fluorescence is recorded at excitation of 325 nm and emission at 400 nm in a microplate spectro-fluorimeter for 20 minutes in 1-minute intervals.
  • IC 50 values are calculated from percentage of inhibition of BACE-activity as a function of the test compound concentration.
  • Recombinant BACE-2 (extracellular domain, expressed in baculovirus and purified using standard methods) at 2.5 nM concentrations is incubated with the test compound at various concentrations for 1 hour at room temperature in 100 mM acetate buffer, pH 4.5, containing 0.1% CHAPS.
  • Synthetic peptide substrate Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(DNP) is added to a final concentration of 3 ⁇ M and the increase in fluorescence is recorded at excitation of 325 nm and emission at 400 nm in a microplate spectro-fluorimeter for 20 minutes in 1-minute intervals.
  • IC 50 values are calculated from percentage of inhibition of BACE-2-activity as a function of the test compound concentration.
  • Recombinant cathepsin D (expressed as procathepsin D in baculovirus, purified using standard methods and activated by incubation in sodium formate buffer pH 3.7) is incubated with the test compound at various concentrations for 1 hour at room temperature in 100 mM sodium formate buffer, pH 3.1.
  • Synthetic peptide substrate Mca-Gly-Lys-Pro-lle-Leu-Phe-Phe-Arg-Leu-Lys(DNP)-D-Arg-NH 2 is added to a final concentration of 2 ⁇ M and the increase in fluorescence is recorded at excitation of 325 nm and emission at 400 nm in a microplate spectro-fluorimeter for 20 minutes in 1-minute intervals.
  • IC 50 values are calculated from percentage of inhibition of cathepsin D-activity as a function of the test compound concentration.
  • Chinese hamster ovary cells are transfected with the gene for amyloid precursor protein.
  • Cells are plated at a density of 8000 cells/well in a 96-well microtiter plate and cultivated for 24 hours in DMEM cell culture medium containing 10% FCS.
  • the test compound is added to the cells at various concentrations, and cells are cultivated for 24 hours in the presence of the test compound.
  • the supernatants are collected, and the concentration of amyloid peptide 1-40 is determined using sandwich ELISA.
  • the potency of the compound is calculated from the percentage of inhibition of amyloid peptide release as a function of the test compound concentration.
  • the agents of the invention show activity at concentrations below 20 ⁇ M.
  • the agents of the invention are therefore useful e.g. for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral haemorrhage with amyloidosis.
  • neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral haemorrhage with amyloidosis.
  • Some of the agents of the invention also inhibit BACE2 (beta-site APP-cleaving enzyme 2) or Cathepsin D, close homologues of the pepsin-type aspartyl proteases. Due to the correlation of BACE2 and CathD expression with a more tumorigenic and metastatic potential of tumor cells, such inhibitors are useful for the suppression of the metastasis process associated with tumor cells.
  • BACE2 beta-site APP-cleaving enzyme 2
  • Cathepsin D close homologues of the pepsin-type aspartyl proteases. Due to the correlation of BACE2 and CathD expression with a more tumorigenic and metastatic potential of tumor cells, such inhibitors are useful for the suppression of the metastasis process associated with tumor cells.
  • the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100, preferably from about 1 to about 50, mg/kg of animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 10 to about 2000, preferably from about 10 to about 200, mg of an agent of the invention conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
  • the agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
  • the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
  • the present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent.
  • a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent.
  • Such compositions may be manufactured in conventional manner.
  • Unit dosage forms contain, for example, from about 1 to about 1000, preferably from about 1 to about 500, mg of an agent of the invention.
  • the agents of the invention can be administered alone or in combination with other pharmaceutical agents effective in the treatment of conditions mentioned above.
  • the pharmaceutical combination may be in the form of a unit dosage form, whereby each unit dosage will comprise a predetermined amount of the two components, in admixture with suitable pharmaceutical carriers or diluents.
  • the combination may be in form of a package containing the two components separately, e.g. a pack or dispenser-device adapted for the concomitant or separate administration of the two active agents, wherein these agents are separately arranged.
  • the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
  • the present invention provides a method for the treatment of any neurological or vascular disorders related to beta-amyloid generation and/or aggregation, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
  • the starting materials can be prepared as described hereafter:
  • reaction mixture is evaporated and the residue column chromatographed (silica gel, EtOAc/petroleum ether 3:2) to yield 1.85 g (46%) 7-(1-methoxycarbonyl-(S)-ethyl) 6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 1.8 g (45%) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester.
  • the absolute stereochemistry is confirmed by X-ray of a sample recrystallized in diisopropylether.
  • reaction mixture is evaporated and the residue column chromatographed (silica gel, EtOAc/petroleum ether 3:2) to yield 1.85 g (46%) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 1.8 g (45%) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester.
  • the absolute stereochemistry is confirmed by X-ray of a sample recrystallized in diisopropylether.
  • reaction mixture Upon completion of the reaction (TLC, EtOAc/petroleum ether 4:1), the reaction mixture is evaporated and the residue taken up in ethyl acetate and treated with an ice-cold, saturated aqueous ammonium chloride solution, then extracted with ethyl acetate and saturated aqueous sodium bicarbonate. The combined organic phases are dried over sodium sulfate, filtered and evaporated to yield the crude desired product as a thick oil.
  • the starting materials can be prepared as described hereafter:
  • reaction mixture is evaporated, the residue taken up in toluene and evaporated to dryness, redissolved in 5 mL isopropanol, treated with 1 mL of a 6N HCl solution in isopropanol and stirred at room temperature for four hours, then evaporated, taken up in toluene and evaporated again to yield the desired product, which is used without further purification.
  • reaction mixture is extracted with EtOAc and saturated aqueous sodium bicarbonate, the combined organic fractions are washed with brine, evaporated and column chromatographed (silica gel, EtOAc/diisopropylether 4:1) to yield 7- ⁇ 1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl ⁇ -6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 7- ⁇ 1-(S)-[1-(R)-(4-(S)-methyl-5-oxo-tetrahydro-furan-2-(R)-yl)-2-phenyl-ethylcarbamoyl]-ethyl ⁇ -6-oxo-1,
  • reaction mixture After stirring for two hours at room temperature, the reaction mixture is cooled below 10° C., quenched with 2 mL of saturated aqueous ammonium chloride and 2 mL of saturated aqueous sodium bicarbonate and stirred an additional 10 minutes before extraction with EtOAc (twice).
  • EtOAc EtOAc
  • the combined organic phases are dried over sodium sulfate, evaporated, and the residue column chromatographed (silica gel, DCM/EtOH/ammonia 90:10:0.05) to yield the desired product as a light-colored resin.
  • the starting materials can be prepared as described hereafter:
  • the starting material can be prepared as described hereafter:
  • This compound can be synthesized as described in Example 1, starting from (1R,4S)-4-fluoro-2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester instead of 2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester.
  • the starting materials can be made as follows:
  • the starting material can be prepared as described hereafter:
  • This compound can be prepared as the compound of Example 6, but starting from 2-(6-oxo-1-prop-2-ynyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester instead of 2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester.
  • the starting material can be prepared as follows:
  • reaction mixture is evaporated, the residue taken up in 15 mL ethanol/toluene 1:2 and evaporated (twice), to yield 2-(S)-(6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester hydrochloride, which is dissolved in 10 mL DMF, treated with 815 mg (5 eq.) cesium carbonate and 0.048 mL (1.25 eq) prop-2-ynyl bromide. The reaction mixture is stirred at room temperature for 18 h, then extracted (AcOEt/water), washed with brine and the combined organic fractions evaporated. The residue is column chromatographed (silica gel, TBME) to yield 78 mg desired product.
  • the desired compound was obtained after HPLC purification of the reaction mixture (column: Nucleosil 100-5 C18 HD, 5 ⁇ m, 250 ⁇ 4.9 mm; eluent: H 2 O/MeCN and 0.1% trifluoroacetic acid; gradient: 9:1 to 1:1 over 20 minutes) and formulation in ethanol to a final concentration of 9.9 microgram/mL (specific activity 68.6 MBq/mL).
  • the tissue of interest is cut in 10 micrometer thick slices for receptor autoradiography with a microtome cryostat and thaw-mounted on silane-coated microscope slides (Vectabond). Sections are air-dried. Preincubation in buffer (50 mM Tris pH 7.4; 2 mM EGTA, 5 mM MgCl2, 0.1 mM bacitracin, 0.2% bovine serum albumine) is for 10 min at air temperature. Ligand binding is done for 1 hr at room temperature in buffer supplemented with 10 nM tritiated compound (specific activity 3.8 TBq/mmol). Non-specific binding is determined in the presence of 10 microM cold compound. Three consecutive washes in buffer and distilled water are followed by air-drying and autoradiography (exposure to Biomax MR film (Eastman Kodak Company) for 4 weeks).
  • buffer 50 mM Tris pH 7.4; 2 mM EGTA, 5 mM MgCl2, 0.1 mM bac
  • the tritiated compound is administrated e.g. i.v. with an appropriate formulation, the animal sacrificed at the time point of desired observation, and the tissue of interest is analyzed for instance as described in Example 9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to novel 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides of the formula
Figure US20070015781A1-20070118-C00001
wherein R1, R2, R3, R4, R5, R6, m and p are as defined in the specification, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions containing them.

Description

  • The present invention relates to novel 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions containing them.
  • More particularly the invention relates to compounds of the formula
    Figure US20070015781A1-20070118-C00002
    wherein
    • R1 is hydrogen or (C1-4)alkyl,
    • R2 is optionally substituted (C1-8)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl or heteroaryl,
    • R3 is —CH(Re)C(═O)N(Ra)Rb or —(CH2)kN(Rc)Rd, wherein
      • k is 0, 1 or 2,
      • Ra, Rb, Ra and Rd, independently, are hydrogen or an optionally substituted (C1-8)alkyl, (C5-9)bicycloalkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl, 4-chromanyl, 1,2,3,4-tetrahydro-quinolin-4-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, thiochroman-4-yl-1,1-dioxide, 4-isochromanyl, 1,2,3,4-tetrahydro-isoquinolin-4-yl, thioisochroman-4-yl-1,1-dioxide, 1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[e][1,2]thiazin-4-yl, 1,1-dioxo-3,4-dihydro-1H-1lambda*6*-benzo[c][1,2]oxathiin-4-yl, 2,2-dioxo-1,2,3,4-tetrahydro-2lambda*6*-benzo[c][1,2]thiazin-4-yl or 2,2-dioxo-3,4-dihydro-2H-2lambda*6*-benzo[e][1,2]oxathiin-4-yl group, or
      • Ra and Rb, or Rc and Rd, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl group, and
      • Re is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, (C3-7)cycloalkyl or (C3-7)cycloalkyl(C1-4)alkyl,
    • R4 is hydrogen or an optionally substituted (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, (C3-7)cycloalkoxy(C1-4)alkyl or aryl group,
    • R5 is hydrogen or optionally substituted (C1-4)alkyl,
    • R6 is hydrogen, hydroxy or halogen, and
    • m and p, independently, are 1 or 2,
    • in free base form or in acid addition salt form.
  • On account of the asymmetrical carbon atoms present in the compounds of the formula I and their salts, the compounds may exist in optically active form or in the form of mixtures of optical isomers, e.g. in the form of racemic mixtures. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention.
  • Further, the compounds of the formula I and their salts may contain a radioisotope, such as tritium, 14C, 11C or 18F. All radiolabeled compounds and their use as biomarkers, in vitro or in vivo imaging agents, or in biochemical assays, e.g. binding assays, are part of the present invention.
  • Substituents on the above defined non-aromatic groups are selected from hydroxy, halogen, carbamoyl, carboxy, hydroxy(C1-4)alkyl, (C1-4)alkoxy, (C1-4)alkoxy(C1-4)alkyl, (C1-4)alkoxy(C1-4)alkoxy, (C1-4)alkylsulfanyl, (C1-4)alkoxycarbonyl, (C1-4)alkylcarbonyloxy, (C1-4)alkylcarbonyl, (C1-4)alkylsulfonyl, cyano, oxo, (C3-7)cycloalkyl, hetero(C3-7)cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl. (C3-7)cycloalkyl or hetero-(C3-7)cycloalkyl groups can also be fused with an additional (C3-7)cycloalkyl, hetero(C3-7)cycloalkyl, or an aromatic or heteroaromatic ring.
  • Substituents on above defined aromatic or heteroaromatic groups are selected from halogen, hydroxy, cyano, nitro, trifluoromethyl, benzyloxy, phenoxy, SO2NH2, NHSO2(C1-3) alkyl, carboxy, (C1-4)alkyloxycarbonyl, carbamoyl, (C1-4)alkylcarbamoyl, (C1-4)alkylsulfonyl, (C1-4)alkylcarbonyloxy, (C1-4)alkylcarbonyl, (C1-6)alkyl, (C1-4)alkoxy, hydroxy(C1-4)alkyl, aryl, heteroaryl or an optionally substituted amino group.
  • Substitutents on amino or carbamoyl groups can be one or two groups selected from (C1-4)alkyl, (C1-4)alkoxy(C1-4)alkyl, (C1-4)alkoxycarbonyl, aryl(C1-4)alkyloxycarbonyl or heteroaryl(C1-4)alkyloxycarbonyl.
  • Aryl is an aromatic 6-membered ring optionally mono-, di- or tri-substituted by, independently, hydroxy, cyano, trifluoromethyl, halogen, carboxy, (C1-4)alkyloxycarbonyl, (C1-4)alkylcarbamoyl, (C1-4)alkylsulfonyl, (C1-4) alkylcarbonyloxy, (C1-4)alkylcarbonylamino, (C1-4)alkylcarbonyl, (C1-6)alkyl, (C1-4)alkoxy or hydroxy(C1-4)alkyl. Aryl groups can also be fused with a (C3-7)cycloalkyl, hetero(C3-7)cycloalkyl or additional aromatic or heteroaromatic ring (e.g. to form a naphthyl, quinolinyl or indolyl group).
  • Heteroaryl is an aromatic 5- or 6-membered ring, in which 1, 2 or 3 atoms are heteroatoms independently selected from O, N and S. Heteroaryl is, for example, 1-methyl-1H-pyrrol-2-yl or 1H-imidazol-2-yl. It can also be fused with a cycloalkyl or additional aromatic or heteroaromatic ring (e.g. to form a quinolinyl or indolyl group).
  • Halogen denotes fluorine, bromine, chlorine or iodine.
  • Any alkyl, alkenyl, alkynyl or alkoxy group is straight or branched.
  • Unless defined otherwise, carbon containing groups and molecules contain 1 to 8, preferably 1 to 6, more preferably 1 to 4, carbon atoms.
  • In a preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R1 is hydrogen.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R2 is aryl, preferably phenyl, more preferably unsubstituted phenyl.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R3 is —CH(Re)C(═O)N(Ra)Rb or —(CH2)kN(Rc)Rd, wherein k is 0; Ra is hydrogen; Rb is (C1-8)alkyl or (C5-9)bicycloalkyl such as bicycloheptyl; Rc is hydrogen; Rd is optionally substituted aryl(C1-4)alkyl, preferably benzyl substituted in the phenyl ring by (C1-4)alkyl, or is optionally substituted (C3-7)cycloalkyl, preferably cyclopropyl substituted by phenyl optionally substituted by halogen, such as bromine, or is 4-chromanyl optionally substituted, preferably by halogen and/or (C1-4)alkyl; and Re is (C1-4)alkyl.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R4 is (C1-8)alkyl, or is (C1-8)alkyl substituted, preferably mono-substituted, by (C3-7)cycloalkyl, preferably cyclopropyl, by halogen, such as fluorine, by (C1-4)alkoxy, or by hydroxy, or is (C2-6)alkenyl optionally substituted, preferably mono-substituted, by hydroxy, or is (C2-6)alkynyl, or is aryl, preferably phenyl, preferably unsubstituted phenyl.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R4 is 2,2,3,3-tetratritiopropyl.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R5 is (C1-8)alkyl, preferably (C1-4)alkyl.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which R6 is hydrogen or halogen, preferably hydrogen or fluorine.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which m is 1.
  • In another preferred embodiment, the invention relates to a compound of the formula I, in free base form or in acid addition salt form, in which p is 1.
  • In a further aspect, the invention relates to a process for the preparation of the compounds of the formula I and their salts, comprising the steps of acylating a compound of the formula
    Figure US20070015781A1-20070118-C00003
    wherein R1, R2 and R3 are as defined above for the formula I, with an acid of the formula
    Figure US20070015781A1-20070118-C00004
    wherein R4, R5, R6, m and p are as defined above for the formula I, or an activated form, such as an ester or an acid halogenide, thereof and recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.
  • The reaction can be effected according to conventional methods, for example as described in the examples.
  • The compounds of the formula I can also be produced by further conventional processes, e.g. as described in the examples.
  • The starting materials of the formulae II and III are known or may be prepared according to conventional procedures starting from known compounds, for example as described in the examples.
  • The working-up of the reaction mixtures and the purification of the compounds thus obtainable may be carried out in accordance with known procedures.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • Compounds of the formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.
  • The agents of the invention are inhibitors of aspartic proteases and can be used for the treatment of disorders involving processing by such enzymes. Particularly they inhibit beta-secretase and as such inhibit the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils.
  • In addition, the agents of the invention exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter “markers”, for the selective labeling of BACE (beta-secretase cleaving enzyme).
  • More particularly the agents of the invention are useful as markers for labeling BACE in vitro or in vivo (see Examples 9 and 10).
  • The agents of the invention are therefore useful, for instance, for determining the levels of active site occupancy of a drug acting at BACE, or for diagnostic purposes for diseases resulting from a dysfunction of BACE-related processes, and for monitoring the effectiveness of pharmacotherapies of such diseases.
  • In accordance with the above, the present invention also provides an agent of the invention for use as a marker for neuroimaging.
  • In a further aspect, the present invention provides a composition for labeling brain and peripheral structures involving BACE in vivo and in vitro comprising an agent of the invention.
  • In still a further aspect, the present invention provides a method for labeling brain and peripheral structures involving BACE in vitro or in vivo, which comprises contacting brain or peripheral tissue with an agent of the invention.
  • The method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure. Said further step may be effected by observing the target structure using autoradiography, positron emission tomography (PET), or any device allowing detection of radioactive radiations.
  • Test 1: Inhibition of Human BACE
  • Recombinant BACE (extracellular domain, expressed in baculovirus and purified using standard methods) at 6 nM concentration is incubated with the test compound at various concentrations for 1 hour at room temperature in 100 mM acetate buffer, pH 4.5, containing 0.1% CHAPS. Synthetic peptide substrate Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(DNP) is added to a final concentration of 3 μM and the increase in fluorescence is recorded at excitation of 325 nm and emission at 400 nm in a microplate spectro-fluorimeter for 20 minutes in 1-minute intervals. IC50 values are calculated from percentage of inhibition of BACE-activity as a function of the test compound concentration.
  • Test 2: Inhibition of Human BACE-2
  • Recombinant BACE-2 (extracellular domain, expressed in baculovirus and purified using standard methods) at 2.5 nM concentrations is incubated with the test compound at various concentrations for 1 hour at room temperature in 100 mM acetate buffer, pH 4.5, containing 0.1% CHAPS. Synthetic peptide substrate Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(DNP) is added to a final concentration of 3 μM and the increase in fluorescence is recorded at excitation of 325 nm and emission at 400 nm in a microplate spectro-fluorimeter for 20 minutes in 1-minute intervals. IC50 values are calculated from percentage of inhibition of BACE-2-activity as a function of the test compound concentration.
  • Test 3: Inhibition of Human Cathepsin D
  • Recombinant cathepsin D (expressed as procathepsin D in baculovirus, purified using standard methods and activated by incubation in sodium formate buffer pH 3.7) is incubated with the test compound at various concentrations for 1 hour at room temperature in 100 mM sodium formate buffer, pH 3.1. Synthetic peptide substrate Mca-Gly-Lys-Pro-lle-Leu-Phe-Phe-Arg-Leu-Lys(DNP)-D-Arg-NH2 is added to a final concentration of 2 μM and the increase in fluorescence is recorded at excitation of 325 nm and emission at 400 nm in a microplate spectro-fluorimeter for 20 minutes in 1-minute intervals. IC50 values are calculated from percentage of inhibition of cathepsin D-activity as a function of the test compound concentration.
  • Test 4: Inhibition of Cellular Release of Amyloid Peptide 1-40
  • Chinese hamster ovary cells are transfected with the gene for amyloid precursor protein. Cells are plated at a density of 8000 cells/well in a 96-well microtiter plate and cultivated for 24 hours in DMEM cell culture medium containing 10% FCS. The test compound is added to the cells at various concentrations, and cells are cultivated for 24 hours in the presence of the test compound. The supernatants are collected, and the concentration of amyloid peptide 1-40 is determined using sandwich ELISA. The potency of the compound is calculated from the percentage of inhibition of amyloid peptide release as a function of the test compound concentration.
  • In at least one of the above-indicated tests, the agents of the invention show activity at concentrations below 20 μM.
  • The agents of the invention are therefore useful e.g. for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral haemorrhage with amyloidosis.
  • Some of the agents of the invention also inhibit BACE2 (beta-site APP-cleaving enzyme 2) or Cathepsin D, close homologues of the pepsin-type aspartyl proteases. Due to the correlation of BACE2 and CathD expression with a more tumorigenic and metastatic potential of tumor cells, such inhibitors are useful for the suppression of the metastasis process associated with tumor cells.
  • For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100, preferably from about 1 to about 50, mg/kg of animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 10 to about 2000, preferably from about 10 to about 200, mg of an agent of the invention conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
  • The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
  • In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
  • The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 1 to about 1000, preferably from about 1 to about 500, mg of an agent of the invention.
  • The agents of the invention can be administered alone or in combination with other pharmaceutical agents effective in the treatment of conditions mentioned above.
  • The pharmaceutical combination may be in the form of a unit dosage form, whereby each unit dosage will comprise a predetermined amount of the two components, in admixture with suitable pharmaceutical carriers or diluents. Alternatively, the combination may be in form of a package containing the two components separately, e.g. a pack or dispenser-device adapted for the concomitant or separate administration of the two active agents, wherein these agents are separately arranged.
  • Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of any neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
  • In still a further aspect, the present invention provides a method for the treatment of any neurological or vascular disorders related to beta-amyloid generation and/or aggregation, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
  • The following Examples illustrate the invention.
  • Abbreviations:
  • BOC tert-butoxycarbonyl
  • BOP benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
  • DAST (Diethylamino)sulfur trifluoride
  • DCM dichloromethane
  • DMF N,N-dimethylformamide
  • DMPU N,N′-dimethylpropyleneurea
  • EDC HCl 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride
  • EtOAc ethylacetate
  • h hours
  • HCl hydrochloric acid
  • HOBt hydroxybenzotriazole
  • HPLC high pressure liquid chromatography
  • LAH lithium aluminum hydride
  • min minutes
  • Mp melting point
  • MS mass spectroscopy
  • Rf retention factor (TLC)
  • rt room temperature
  • TBAF tetrabutylammonium fluoride
  • TBME tert-butyl methyl ether
  • TBTU O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-tetrafluoroborate
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • TLC thin-layer chromatography
    • EXAMPLE 1 4-(S)-hydroxy-5-(S)-[2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • 113 mg (0.4 mmol) of 2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester are dissolved in 18 ml of THF and treated with 2 mL of a 0.5 N aqueous LiOH solution and stirred at room temperature for four hours. The reaction mixture is cooled to 5° C. and treated with an aqueous 1N HCl solution until a pH of 4 is reached. The solution is submitted to two consecutive azeotropic evaporations with 80 mL toluene and the residue dried under high vacuum, then taken up in 20 mL dichloromethane and stirred at room temperature for twenty hours with 117 mg (0.4 mmol) 5-(S)-amino-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide, 85 mg (0.44 mmol) EDC.HCl, 54 mg (0.4 mmol) HOBt and 0.17 mL triethylamine (1.2 mmol). The reaction mixture is quenched with 10 mL ice-cold saturated aqueous sodium bicarbonate solution, then extracted twice with dichloromethane. The combined organic phases are evaporated and the residue is column chromatographed (silica gel, TBME/EtOAc/EtOH 49:59:2) to yield after evaporation of the pure fractions the desired product as a colorless resin.
  • MS(El+): 453 (M+1)
  • The starting materials can be prepared as described hereafter:
    • a) 2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester
  • 260 mg (0.8 mmol) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester is stirred in 3 mL of a 4N solution HCl in dioxane for three hours at room temperature, then evaporated. The residue is taken up in toluene and evaporated to dryness (twice), then taken up in 6 mL methanol, treated with 0.145 mL (1.6 mmol) isobutyraldehyde, 300 mg 3 Å powdered molecular sieve and 100 mg (1.6 mmol) sodium cyanoborohydride and stirred overnight at room temperature. The reaction mixture is treated with 4 mL saturated aqueous ammonium chloride solution and after 10 minutes with 8 mL saturated aqueous sodium bicarbonate, then extracted with EtOAc. The combined organic phases are evaporated and the residue column chromatographed (silica gel, EtOAc) to yield after evaporation of the corresponding fractions the desired product as a colorless oil.
  • MS (ES+): 283 (M+1)
    • b) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 7-(1-Methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4nonane-1-carboxylic acid tert-butyl ester
  • 4.3 g (12 mmol) 2-[2-(1-methoxycarbonyl-ethylamino)-(S)-ethyl]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester are dissolved in 60 mL xylene and heated to 150° C. for two hours. The reaction mixture is evaporated and the residue column chromatographed (silica gel, EtOAc/petroleum ether 3:2) to yield 1.85 g (46%) 7-(1-methoxycarbonyl-(S)-ethyl) 6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 1.8 g (45%) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester. The absolute stereochemistry is confirmed by X-ray of a sample recrystallized in diisopropylether.
    • c) 2-[2-(1-methoxycarbonyl-(S)-ethylamino)-ethyl]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  • 271 mg (1 mmol) 2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester and 154 mg (1.1 mmol) L-alanine methyl ester hydrochloride are suspended in 10 mL toluene and treated with 0.073 mL (1 eq.) triethylamine. The reaction mixture is stirred 10
    • a) 2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester
  • 260 mg (0.8 mmol) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester is stirred in 3 mL of a 4N solution HCl in dioxane for three hours at room temperature, then evaporated. The residue is taken up in toluene and evaporated to dryness (twice), then taken up in 6 mL methanol, treated with 0.145 mL (1.6 mmol) isobutyraldehyde, 300 mg 3 Å powdered molecular sieve and 100 mg (1.6 mmol) sodium cyanoborohydride and stirred overnight at room temperature. The reaction mixture is treated with 4 mL saturated aqueous ammonium chloride solution and after 10 minutes with 8 mL saturated aqueous sodium bicarbonate, then extracted with EtOAc. The combined organic phases are evaporated and the residue column chromatographed (silica gel, EtOAc) to yield after evaporation of the corresponding fractions the desired product as a colorless oil.
  • MS (ES+): 283 (M+1)
    • b) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 7-(1-Methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester
  • 4.3 g (12 mmol) 2-[2-(1-methoxycarbonyl-ethylamino)(S)-ethyl]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester are dissolved in 60 mL xylene and heated to 150° C. for two hours. The reaction mixture is evaporated and the residue column chromatographed (silica gel, EtOAc/petroleum ether 3:2) to yield 1.85 g (46%) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 1.8 g (45%) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester. The absolute stereochemistry is confirmed by X-ray of a sample recrystallized in diisopropylether.
    • c) 2-[2-(1-methoxycarbonyl-(S)-ethylamino)-ethyl]-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  • 271 mg (1 mmol) 2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester and 154 mg (1.1 mmol) L-alanine methyl ester hydrochloride are suspended in 10 mL toluene and treated with 0.073 mL (1 eq.) triethylamine. The reaction mixture is stirred 10 minutes at room temperature and slowly evaporated in a rotary evaporator. The residue is taken up in 15 mL acetonitrile and 95 mg (1.5 mmol) sodium cyanoborohydride in 2 mL methanol added dropwise. Upon completion of the reaction (TLC, EtOAc/petroleum ether 4:1), the reaction mixture is evaporated and the residue taken up in ethyl acetate and treated with an ice-cold, saturated aqueous ammonium chloride solution, then extracted with ethyl acetate and saturated aqueous sodium bicarbonate. The combined organic phases are dried over sodium sulfate, filtered and evaporated to yield the crude desired product as a thick oil.
  • MS(El+): 359 (M+1)
  • Rf(EtOAc): 0.22
    • d) 5-(S)-amino-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • 32 mg (0.1 mmol) [1-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-(S)-phenyl-ethyl]-carbamic acid tert-butyl ester are stirred at room temperature for two hours in 1 mL of a 4N HCl solution in dioxane. The reaction mixture is evaporated to dryness, the residue taken up in toluene and evaporated to dryness twice before drying under high vacuum. The residue is taken up in 1 mL (excess) butylamine and stirred at 25° C. overnight, then evaporated and the residue extracted twice with ethyl acetate and saturated sodium bicarbonate. The combined organic phases are evaporated, the crude desired product obtained quantitatively as a colorless resin and used without further purification.
  • MS(El+): 293 (M+1).
  • The following compounds can be obtained by a similar procedure:
    • EXAMPLE 1a 5-(S)-[2-(S)-(1-cyclopropylmethyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 541 (M+1)
    • EXAMPLE 1b 5-(S)-[2-(S)-(1-propyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino-]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 529 (M+1)
    • EXAMPLE 1c 5-(S)-[2-(S)-(1-phenyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 591 (M+1)
    • EXAMPLE 1d 5-(S)-[2-(S)-(1-phenyl-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 591 (M+1)
    • EXAMPLE 1e 4-(S)-hydroxy-2-(R)-methyl-5-(S)-[2-(S)-(6-oxo-1-propyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-6-phenyl-hexanoic acid (2,2-dimethyl-propyl)-amide
  • MS(El+): 543 (M+1)
    • EXAMPLE 1f 5-(S)-[2-(S)-(1-cyclopropylmethyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid bicyclo[2.2.1]hept-exo-2-(R,S)-ylamide
  • MS(El+): 579 (M+1)
    • EXAMPLE 1g 5-(S)-{2-(S)-[1-(2,2-dimethyl-propyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl]-propionylamino}-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 557 (M+1)
    • EXAMPLE 1h 4-(S)-hydroxy-5-(S)-{2-(S)-[1-(3-methoxy-propyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl-]-propionylamino}-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 559 (M+1)
    • EXAMPLE 1i 5-(S)-[2-(S)-(1-cyclopropylmethyl-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid bicyclo[2.2.1]hept-exo-2-(R,S)-ylamide
  • MS(El+): 579 (M+1)
    • EXAMPLE 1j 4-(S)-hydroxy-5-(S)-{2-(S)-[1-(3-methoxy-propyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl]-propionylamino}-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 559 (M+1)
    • EXAMPLE 1k 5-(S)-2-(S)-(1-propyl-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 529 (M+1)
    • EXAMPLE 1l 4-(S)-hydroxy-5-(S)-[2-(S)-(1-(2-fluoroethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 533 (M+1)
    • EXAMPLE 2 5-(S)-[2-(S)-(1-allyl-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • 52 mg (0.1 mmol) 4-(S)-hydroxy-2-(R)-methyl-5-(S)-[2-(S)-(6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-6-phenyl-hexanoic acid butyl amide hydrochloride, 28 mg potassium carbonate and 0.01 mL allyl bromide are stirred at room temperature for 65 hours in 3 mL DMF, then extracted with EtOAc and brine (twice). The combined organic phases are dried over sodium sulfate, evaporated and column chromatographed to yield the desired product as a light-colored resin.
  • MS(El+): 527 (M+1)
  • The starting materials can be prepared as described hereafter:
    • a) 4-(S)-hydroxy-2-(R)-methyl-5-(S)-[2-(S)-(6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-6-phenyl-hexanoic acid butyl amide hydrochloride
  • 170 mg (0.33 mmol) 7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester are dissolved in 1.5 mL (excess) butylamine and heated to 65° C. under argon for two hours. The reaction mixture is evaporated, the residue taken up in toluene and evaporated to dryness, redissolved in 5 mL isopropanol, treated with 1 mL of a 6N HCl solution in isopropanol and stirred at room temperature for four hours, then evaporated, taken up in toluene and evaporated again to yield the desired product, which is used without further purification.
  • MS (El+): 487 (M+1)
    • b) 7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 7-{1-(S)-[1-(R)-(4-(S)-methyl-5-oxo-tetrahydro-furan-2-(R)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester
  • 326 mg (1 mmol) 7-(1-(S)-methoxycarbonyl-ethyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester are dissolved in 15 mL THF, cooled to 10° C. and treated with 7 mL (1.05 eq) of a 0.15 N THF solution of LiOH. After two hours stirring at room temperature, a 1 N aqueous HCl solution is added until a pH of 4 was reached, and the reaction mixture evaporated. The residue is taken up in toluene, evaporated to dryness and dried under high vacuum, then taken up in 20 mL dichloromethane and stirred for 18 hours after addition of 230 mg racemic 5-(1-amino-2-phenyl-ethyl)-3-methyl-dihydro-furan-2-one, 135 mg HOBt (1 mmol), 208 mg EDC.HCl (1.1 mmol) and 0.031 mL triethylamine (2.25 mmol). The reaction mixture is extracted with EtOAc and saturated aqueous sodium bicarbonate, the combined organic fractions are washed with brine, evaporated and column chromatographed (silica gel, EtOAc/diisopropylether 4:1) to yield 7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester and 7-{1-(S)-[1-(R)-(4-(S)-methyl-5-oxo-tetrahydro-furan-2-(R)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester is white solids in respectively 33 and 30% yields.
  • The absolute stereochemistry is confirmed by comparison with optically pure material made from 5-(S)-1-(S)-amino-2-phenyl-ethyl)-3-(R)-methyl-dihydro-furan-2-one.
  • MS(El+): 514 (M+1)
  • The following compounds can be obtained by a similar procedure:
    • EXAMPLE 2a 5-(R)-[2-(S)-(1-allyl-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl)-propionylamino]-4-(R)-hydroxy-2-(S)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 527 (M+1)
    • EXAMPLE 2b 5-(R)-[2-(S)-(1-allyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-4-(R)-hydroxy-2-(S)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 527 (M+1)
    • EXAMPLE 2c 5-(S)-[2-(S)-(1-allyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 527 (M+1)
    • EXAMPLE 3 4-(S)-hydroxy-5-(S)-{2-(S)-[1-(4-hydroxy-butyl)-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-7-yl]-propionylamino}-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • 30 mg (0.06 mmol) 4-(7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-1-yl)-butyric acid methyl ester are stirred overnight at room temperature in 1 mL butylamine. The reaction mixture is evaporated to dryness, taken up in toluene and evaporated again, and the residue dissolved in THF, cooled to 5° C. and treated with 3 mg (2 eq.) lithium borohydride. After stirring for two hours at room temperature, the reaction mixture is cooled below 10° C., quenched with 2 mL of saturated aqueous ammonium chloride and 2 mL of saturated aqueous sodium bicarbonate and stirred an additional 10 minutes before extraction with EtOAc (twice). The combined organic phases are dried over sodium sulfate, evaporated, and the residue column chromatographed (silica gel, DCM/EtOH/ammonia 90:10:0.05) to yield the desired product as a light-colored resin.
  • MS(El+): 559 (M+1)
  • The starting materials can be prepared as described hereafter:
    • a) 4-(7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-1-yl)-butyric acid methyl ester
  • 30 mg (0.06 mmol) 4-(7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-1-yl)-but-2-enoic acid methyl ester are stirred in THF under hydrogen for two hours in the presence of a catalytic amount of 10% Pd/C, then filtered through celite and evaporated to yield 30 mg desired product, which is used without further purification.
  • MS(El+): 514 (M+1)
    • b) 4-(7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-6-oxo-1,7-diaza-spiro-(R)-[4.4]non-1-yl)-but-2-enoic acid methyl ester
  • 130 mg (0.25 mmol) 7-{1-(S)-[1-(S)-(4-(R)-methyl-5-oxo-tetrahydro-furan-2-(S)-yl)-2-phenyl-ethylcarbamoyl]-ethyl}-oxo-1,7-diaza-spiro-(R)-[4.4]nonane-1-carboxylic acid tert-butyl ester are dissolved in 2 mL of 4N HCl in dioxane. The reaction mixture is evaporated after 90 minutes, taken up in toluene and evaporated to dryness. The residue is taken up in dichloromethane and stirred at room temperature for 18 hours in the presence of 92 mg (1 eq.) tetrabutylammonium iodide, 0.03 mL trans-4-bromobut-2-enoic acid methyl ester and 0.09 mL (2 eq.) diisopropylethylamine. The reaction mixture is extracted with dichloromethane and aqueous bicarbonate (twice), the combined organic phases evaporated and the residue column chromatographed (silica gel, EtOAc) to yield the desired product as a slightly brownish resin.
  • MS(El+): 512 (M+1)
  • The following compound can be obtained by a similar procedure:
    • EXAMPLE 3a 4-(S)-hydroxy-5-(S)-{2-(S)-[1-(4-hydroxy-butyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl]-propionylamino}-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 559 (M+1)
    • EXAMPLE 4 4-hydroxy-5-{2-[1-(4-hydroxy-but-2-enyl)-6-oxo-1,7-diaza-spiro[4.4]non-7-yl]-propionylamino}-2-methyl-6-phenyl-hexanoic acid butylamide
  • MS(El+): 557 (M+1)
  • is obtained in a similar manner to example 1, but using 2-[1-(4-hydroxy-but-2-enyl)-6-oxo-1,7-diaza-spiro[4.4]non-7-yl]-propionic acid methyl ester in step 1a.
  • The starting material can be prepared as described hereafter:
    • 2-[1-(4-hydroxy-but-2-enyl)-6-oxo-1,7-diaza-spiro[4.4]non-7-yl]-propionic acid methyl ester
  • 82 mg (0.25 mmol) (S,S)-7-(1-methoxycarbonyl-ethyl)-6-oxo-1,7-diaza-spiro[4.4]nonane-1-carboxylic acid tert-butyl ester are stirred at room temperature for three hours in 1 mL of a 4N HCl dioxane solution, evaporated, then taken up in toluene and evaporated again (twice). The residue is taken up in 2 mL dichloromethane and stirred at room temperature for 65 hours in the presence of 74 mg (0.2 mmol) tetrabutylammonium iodide, 0.035 mL (0.2 mmol) diisopropylethylamine and 30 mg (0.2 mmol) 4-bromo-but-2-en-1-ol. The reaction mixture is extracted with EtOAc and saturated aqueous sodium bicarbonate, the combined organic phases washed with brine, evaporated to dryness and the residue column chromatographed (slica gel, EtOAc/EtOH 9:1) to yield the desired product as a thick liquid.
  • MS(El+): 297 (M+1)
    • EXAMPLE 5 5-(S)-[2-(S)-(3-(S)-fluoro-6-oxo-1-propyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionylamino]-4-(S)-hydroxy-2-(R)-methyl-6-phenyl-hexanoic acid butylamide
  • This compound can be synthesized as described in Example 1, starting from (1R,4S)-4-fluoro-2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester instead of 2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester.
  • MS(El+): 547 (M+1)
  • The starting materials can be made as follows:
    • a) (2R,4S)-4-fluoro-2-(2-oxo-ethyl)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  • 1 g (3.5 mmol) (2R,4S)-2-allyl-4-fluoro-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester is dissolved in 60 mL dichloromethane/methanol 1:1, cooled to −78° C., flushed with oxygen for two minutes then treated with a flux of ozone until the solution turns light blue. The solution is allowed to warm up to room temperature after addition of 1 g (1.1 eq.) triphenylphosphine, stirred an additional 5 h and column chromatographed (silica gel, TBME/petroleum ether 3:2) to yield 870 mg of the desired product as a clear oil.
  • MS (El+): 290 (M+1).
    • b) (2R,4S)-2-allyl-fluoro-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  • 0.39 mL DAST (1.2 eq) are dissolved in 30 mL dichloromethane, cooled to −78° C. and treated over 10 min. with a dropwise addition of 10 mL dichloromethane containing 1.8 g (6.3 mmol) (2R,4R)-2-allyl-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester. The solution is allowed to reach room temperature under stirring, over 2 h. After cooling below 5° C. the reaction mixture is treated with an ice-cold saturated aqueous sodium carbonate solution and extrated with dichloromethane. The combined extracts are washed with brine and dried over sodium sulphate, evaporated and the residue column chromatographed (silica gel, TBME/petroleum ether 1:1) to yield 1 g desired product as a colorless thick oil.
  • MS(El+): 288 (M+1)
    • c) (2R,4R)-2-allyl-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  • 3.3 g (8.27 mmol) (2R,4R)-(2-allyl-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester are dissolved in 60 mL THF, cooled below 5° C. and treated with 8.68 mL (1.05 eq) 1 M TBAF in THF under stirring. The reaction mixture is allowed to slowly reach room temperature, while being stirred another 4 h. Ice and AcOEt are added, the mixture washed with brine twice, and the organic phase evaporated to yield a crude product which is column chromatographed (silica gel, TBME/petroleum ether 1:1) to yield 1.8 g desired product as a colorless, thick oil, which is used as such in the next step.
    • EXAMPLE 6 (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-((S)-6-oxo-1-propyl-1,7-diaza-spiro[4.4]non-7-yl)-propionamide
  • A solution of 100 mg (2R,3S)-3-amino-1-(3-isopropyl-benzylamino)-4-phenyl-butan-2-ol dihydrochloride, 79 mg (S-2-((S)-6-oxo-1-propyl-1,7-diaza-spiro[4.4]non-7-yl)-propionic acid, 102 mg TBTU and 0.171 mL N-methyl morpholine in 5 mL CH2Cl2 is stirred for 5 h at ambient temperature. The solution is diluted with DCM and subsequently washed with bicarbonate, brine, 0.1N HCl and bicarbonate. After drying with MgSO4 all volatiles are evaporated in vacuo and the product is purified by column chromatography (silica gel, DCM/MeOH 95:5) to give 53 mg (37%) of the desired product.
  • MS-ESl+: 549 [M+]
  • Rf: 0.28 (CH2Cl2/MeOH=9/1)
  • The starting material can be prepared as described hereafter:
    • a) (2R,3S)-3-amino-1-(3-isopropyl-benzylamino)-4-phenyl-butan-2-ol-dihydrochloride
  • A solution of 700 mg (2.7 mmol) tert-butyl(S—(R,R)(-)-(1-oxiranyl-2-phenylethyl)-carbamate and 470 mg (3.3 mmol) 3-iso-propylbenzylamine in 10 ml EtOH is heated for 15 h at 50° C. Evaporation of the solvent and purification by column chromatography (silica gel, DCM/MeOH 9:1) afforded 820 mg of [(1S,2R)-1-benzyl-2-hydroxy-3-(3-iso-propyl-benzylamino)-propyl]-carbamic acid tert-butyl ester as a colourless solid. This material is dissolved in 10 ml 4N HCl in dioxane, stirred for 2 h at ambient temperature and all volatiles removed in vacuo to give 643 mg desired compound.
  • The following compounds can be obtained by a similar procedure:
    • EXAMPLE 6a (S)-N-[(1S,2R)-1-benzyl-3-(6-bromo-2,2-dimethyl-chroman-4-ylamino)-2-hydroxy-propyl]-2-((S)-1-cyclopropylmethyl-6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamide
  • MS(El+): 667, 669 (M+1)
    • EXAMPLE 6b (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-((S)-1-cyclopropylmethyl-3-(S)-fluoro-6-oxo-1,7-diaza-spiro-[4.4]non-7-yl)-propionamide
  • MS(El+): 579 (M+1)
    • EXAMPLE 6c (S)-N-[(1S, 2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-((S)-1-propyl-3-(S)-fluoro-6-oxo-1,7-diaza-spiro-[4.4]non-7-yl)-propionamide
  • MS(El+): 567 (M+1)
    • EXAMPLE 6d (S)-N-{(1S,2R)-1-benzyl-3-[1-(3-bromo-phenyl)-cyclopropylamino]-2-hydroxy-propyl}-2-((S)-1-cyclopropylmethyl-3-(S)-fluoro-6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamide
  • MS(El+): 641, 643 (M+1)
    • EXAMPLE 6e (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-[(S)-1-(2-fluoro-ethyl)-6-oxo-1,7-diaza-spiro[4.4]non-7-yl]-propionamide
  • MS(El+): 553 (M+1)
    • EXAMPLE 6f (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-((S)-1-cyclopropylmethyl-6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamide
  • MS(El+): 561 (M+1)
    • EXAMPLE 7 (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-((S)-6-oxo-1-prop-2-ynyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionamide
  • This compound can be prepared as the compound of Example 6, but starting from 2-(6-oxo-1-prop-2-ynyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester instead of 2-(S)-(1-isobutyl-6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester.
  • The starting material can be prepared as follows:
    • 7a) 2-(S)-(6-oxo-1-prop-2-ynyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester
  • 163 mg (0.5 mmol) 7-(1-methoxycarbonyl-(S)-ethyl)-6-oxo-1,7-diaza-spiro-(S)-[4.4]nonane-1-carboxylic acid tert-butyl ester are dissolved in 1.5 mL 4N HCl in dioxane and stirred for 3 h at room temperature. The reaction mixture is evaporated, the residue taken up in 15 mL ethanol/toluene 1:2 and evaporated (twice), to yield 2-(S)-(6-oxo-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionic acid methyl ester hydrochloride, which is dissolved in 10 mL DMF, treated with 815 mg (5 eq.) cesium carbonate and 0.048 mL (1.25 eq) prop-2-ynyl bromide. The reaction mixture is stirred at room temperature for 18 h, then extracted (AcOEt/water), washed with brine and the combined organic fractions evaporated. The residue is column chromatographed (silica gel, TBME) to yield 78 mg desired product.
  • MS(El+): 265 (M+1)
    • EXAMPLE 8 (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropylbenzylamino)propyl]-2-((S)-6-oxo-1-(2,2,3,3-tetratritiopropyl)-1,7-diaza-spiro[4,4]non-7-yl)-propionamide
  • (S)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-isopropyl-benzylamino)-propyl]-2-((S)-6-oxo-1-prop-2-ynyl-1,7-diaza-spiro-(S)-[4.4]non-7-yl)-propionamide was reduced under 0.9 atmosphere tritium gas on 10% Pd/C for 2 h. The desired compound was obtained after HPLC purification of the reaction mixture (column: Nucleosil 100-5 C18 HD, 5 μm, 250×4.9 mm; eluent: H2O/MeCN and 0.1% trifluoroacetic acid; gradient: 9:1 to 1:1 over 20 minutes) and formulation in ethanol to a final concentration of 9.9 microgram/mL (specific activity 68.6 MBq/mL).
  • HPLC: RT=12.87 min
  • ME (ES+): 557 (M+1)
    • EXAMPLE 9 In Vitro Autoradiography
  • The tissue of interest is cut in 10 micrometer thick slices for receptor autoradiography with a microtome cryostat and thaw-mounted on silane-coated microscope slides (Vectabond). Sections are air-dried. Preincubation in buffer (50 mM Tris pH 7.4; 2 mM EGTA, 5 mM MgCl2, 0.1 mM bacitracin, 0.2% bovine serum albumine) is for 10 min at air temperature. Ligand binding is done for 1 hr at room temperature in buffer supplemented with 10 nM tritiated compound (specific activity 3.8 TBq/mmol). Non-specific binding is determined in the presence of 10 microM cold compound. Three consecutive washes in buffer and distilled water are followed by air-drying and autoradiography (exposure to Biomax MR film (Eastman Kodak Company) for 4 weeks).
    • EXAMPLE 10 Ex Vivo Autoradiography
  • The tritiated compound is administrated e.g. i.v. with an appropriate formulation, the animal sacrificed at the time point of desired observation, and the tissue of interest is analyzed for instance as described in Example 9.

Claims (10)

1. A compound of the formula
Figure US20070015781A1-20070118-C00005
wherein
R1 is hydrogen or (C1-4)alkyl,
R2 is optionally substituted (C1-8)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl or heteroaryl,
R3 is —CH(Re)C(═O)N(Ra)Rb or —(CH2)kN(Rc)Rd, wherein
k is 0, 1 or 2,
Ra, Rb, Rc and Rd, independently, are hydrogen or an optionally substituted (C1-8)alkyl, (C5-9)bicycloalkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl, 4-chromanyl, 1,2,3,4-tetrahydro-quinolin-4-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, thiochroman-4-yl-1,1-dioxide, 4-isochromanyl, 1,2,3,4-tetrahydro-isoquinolin-4-yl, thioisochroman-4-yl-1,1-dioxide, 1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[e][1,2]thiazin-4-yl, 1,1-dioxo-3,4-dihydro-1H-1lambda*6*-benzo[c][1,2]oxathiin-4-yl, 2,2-dioxo-1,2,3,4-tetrahydro-2lambda*6*-benzo[c][1,2]thiazin-4-yl or 2,2-dioxo-3,4-dihydro-2H-2lambda*6*-benzo[e][1,2]oxathiin-4-yl group, or
Ra and Rb, or Rc and Rd, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl group, and
Re is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, (C3-7)cycloalkyl or (C3-7)cycloalkyl(C1-4)alkyl,
R4 is hydrogen or an optionally substituted (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, (C3-7)cycloalkoxy(C1-4)alkyl or aryl group,
R5 is hydrogen or optionally substituted (C1-4)alkyl,
R6 is hydrogen, hydroxy or halogen, and
m and p, independently, are 1 or 2,
in free base form or in acid addition salt form.
2. A process for the preparation of a compound as defined in claim 1 of the formula I, in free base form or in acid addition salt form, comprising the steps of acylating a compound of the formula
Figure US20070015781A1-20070118-C00006
wherein R1, R2 and R3 are as defined for the formula I, with an acid of the formula
Figure US20070015781A1-20070118-C00007
wherein R4, R5, R6, m and p are as defined for the formula I, or an activated form, such as an ester or an acid halogenide, thereof and recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.
3. A compound according to claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
4. A compound according to claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, for use in the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
5. A pharmaceutical composition comprising a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, as active ingredient and a pharmaceutical carrier or diluent.
6. The use of a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
7. The use of a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation.
8. A method for the treatment of neurological or vascular disorders related to beta-amyloid generation and/or aggregation in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form.
9. A combination comprising a therapeutically effective amount of a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, and a second drug substance, for simultaneous or sequential administration.
10. The use of a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, as histopathological labeling agent, imaging agent and/or biomarker for the selective labeling of the beta-secretase cleaving enzyme BACE.
US10/574,536 2003-10-03 2004-10-04 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals Abandoned US20070015781A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/823,311 US7655686B2 (en) 2003-10-03 2007-06-26 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0323204.8 2003-10-03
GBGB0323204.8A GB0323204D0 (en) 2003-10-03 2003-10-03 Organic compounds
PCT/EP2004/011054 WO2005035535A1 (en) 2003-10-03 2004-10-04 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/823,311 Continuation US7655686B2 (en) 2003-10-03 2007-06-26 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Publications (1)

Publication Number Publication Date
US20070015781A1 true US20070015781A1 (en) 2007-01-18

Family

ID=29415468

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/574,536 Abandoned US20070015781A1 (en) 2003-10-03 2004-10-04 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals
US11/823,311 Expired - Fee Related US7655686B2 (en) 2003-10-03 2007-06-26 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/823,311 Expired - Fee Related US7655686B2 (en) 2003-10-03 2007-06-26 Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Country Status (15)

Country Link
US (2) US20070015781A1 (en)
EP (1) EP1670803B1 (en)
JP (1) JP4549350B2 (en)
CN (1) CN1863804B (en)
AT (1) ATE388954T1 (en)
AU (1) AU2004279553C1 (en)
BR (1) BRPI0415015A (en)
CA (1) CA2540249A1 (en)
DE (1) DE602004012426T2 (en)
ES (1) ES2300815T3 (en)
GB (1) GB0323204D0 (en)
MX (1) MXPA06003645A (en)
PL (1) PL1670803T3 (en)
PT (1) PT1670803E (en)
WO (1) WO2005035535A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508166A (en) * 2002-11-27 2006-03-09 イーラン ファーマスーティカルズ、インコーポレイテッド Substituted ureas and carbamates
JP2008543841A (en) * 2005-06-14 2008-12-04 シェーリング コーポレイション Macrocyclic heterocyclic aspartyl protease inhibitors
EP1910364B1 (en) * 2005-07-18 2012-03-21 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
MX2011003015A (en) 2008-09-18 2011-11-18 Univ Northwestern Nmda receptor modulators and uses thereof.
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
PL2951183T3 (en) 2013-01-29 2019-08-30 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP2951182B1 (en) 2013-01-29 2020-03-18 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (en) 2013-01-29 2015-10-02 노렉스, 인크. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120789A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX383650B (en) 2016-08-01 2025-03-14 Aptinyx Inc NMDA SPIRO-LACTAM RECEPTOR MODULATORS AND THEIR USE.
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
PE20190500A1 (en) 2016-08-01 2019-04-10 Aptinyx Inc NMDA SPIRO-LACTAM RECEIVER MODULATORS AND THE SAME USE
BR112019001923A2 (en) 2016-08-01 2019-05-14 Aptinyx Inc. Spiro-lactam nmda modulators and methods of their use
CN109890825B (en) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 Spiro-lactam NMDA receptor modulators and uses thereof
JP7210599B2 (en) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド Spirolactam-based NMDA receptor modulators and uses thereof
MA56550A (en) * 2019-06-24 2022-04-27 Naurex Inc SOLID FORMS OF TERT-BUTYL (S)-2-((2S,3R)-1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO -2, 5-DIAZASPIRO[3,4 ]OCTANE-5-CARBOXYLATE AND METHODS FOR THE PREPARATION THEREOF
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20240174673A1 (en) * 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
DK0970957T3 (en) * 1998-06-12 2001-12-03 Hoffmann La Roche Diazaspiro [3.5] nonane derivatives
AU2492500A (en) * 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
JP2008524167A (en) * 2004-12-20 2008-07-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ MyD88 homodimerization inhibitor

Also Published As

Publication number Publication date
PT1670803E (en) 2008-04-23
DE602004012426T2 (en) 2009-03-26
DE602004012426D1 (en) 2008-04-24
EP1670803A1 (en) 2006-06-21
PL1670803T3 (en) 2008-08-29
ES2300815T3 (en) 2008-06-16
EP1670803B1 (en) 2008-03-12
ATE388954T1 (en) 2008-03-15
JP2007509038A (en) 2007-04-12
JP4549350B2 (en) 2010-09-22
MXPA06003645A (en) 2006-06-05
CN1863804A (en) 2006-11-15
CA2540249A1 (en) 2005-04-21
GB0323204D0 (en) 2003-11-05
BRPI0415015A (en) 2006-11-07
AU2004279553B2 (en) 2009-03-12
AU2004279553A1 (en) 2005-04-21
US20070265328A1 (en) 2007-11-15
CN1863804B (en) 2010-05-26
AU2004279553C1 (en) 2009-07-23
HK1092472A1 (en) 2007-02-09
US7655686B2 (en) 2010-02-02
WO2005035535A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US7655686B2 (en) Certain substituted spirocyclic lactams and use thereof as pharmaceuticals
US20240262867A1 (en) Hybrid cyclic libraries and screens thereof
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
EP3344616B1 (en) Substituted amino triazoles useful as human chitinase inhibitors
EP1572113B1 (en) Calcium receptor modulating compound and use thereof
RU2266906C1 (en) Anellated carbamoyl azaheterocycles, methods for their preparing (variants), pharmaceutical composition, focused library
US20200109167A1 (en) Small molecule dcn1 inhibitors and therapeutic methods using the same
HK1249510A1 (en) Substituted amino triazoles useful as human chitinase inhibitors
EP3010925B1 (en) Bace inhibitors
US20190322682A1 (en) Thienopyrimidinone compounds
WO2018235966A1 (en) EP300 / CREBBP inhibitor
US9309248B2 (en) Azaindolines
JP2015534569A (en) Azaindoline
US20080070885A1 (en) Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
RU2281947C1 (en) Anellated cabamoylazaheterocycles, focused library, pharmaceutical composition and method for its preparing
HK1092472B (en) Certain substituted spirocyclic lactams and use thereof as pharmaceuticals
JP2008536834A (en) [6,7-Dihydro-5H imidazo [1,2-α] imidazol-3-sulfonyl] -azetedin-carboxylic acid, esters and amide derivatives and their use as anti-inflammatory agents
CN116171272A (en) Novel VDAC1 inhibitors
US20080311609A1 (en) Novel Molecular Probes
EP4269400B1 (en) Ykl-40 inhibitors and their therapeutic applications
CN115996930A (en) Aminopyrimidinyl derivatives
EA045146B1 (en) HETEROAROMATIC COMPOUNDS AS VANINE INHIBITORS

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION